YUAN Yuhe
Principal Investigator
Professor Yuan Yuhe is an principal investigator. The main research direction of her group is to explore the pathogenesis of Parkinson's disease (PD) based on cell and animal models, and to develop innovative drugs for the treatment of PD. In the past five years, a total of 10 projects have been supported. During the past five years, more than 30 papers have been published, and 5 patents have been applied for.
1. Tunneling Nanotubes: A Novel Pharmacological Target for Neurodegenerative Diseases? Pharmacol Res . 2021:105541. doi: 10.1016/j.phrs.2021.105541.
2. A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules. Int Immunopharmacol. 2021;91:107269. doi: 10.1016/j.intimp.2020.107269.
3. Research on developing drugs for Parkinson's disease. Brain Res Bull . 2021 ;168:100-109.
4. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry . 2020:109745. doi: 10.1016/j.pnpbp.2019.109745.
5. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. Acta Pharmacol Sin . 2019, 40(8):991-998.
6. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease. Acta Pharmacol Sin . 2019，40(12):1503-1512.
7. Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2 cells. Neuropharmacology. 2019, 144，388-399.
8. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. International Immunopharmacology. 2019；67 ：458–464.
9. NLRP3 inflammasome activation in the thymus of MPTP-induced Parkinsonian mouse model. Toxicol Lett. 2018, 5(288):1-8.
10. Anti-neuroinflammatory effects of 20C from Gastrodia elata via regulating autophagy in LPS-activated BV-2 cells through MAPKs and TLR4/Akt/mTOR signaling pathways. Mol Immunol . 2018;99:115-123.
11. Prion-like propagation of α-synuclein in the gut-brain axis. Brain Res Bull . 2018，140:341-346.
12. A novel bibenzyl compound, 20C, protected mice from MPTP/p toxicity by regulating alpha-synuclein related inflammatory response. J Pharmacol Exp Ther. 2017;363(2):284-292.
13. Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. Acta Pharmacologica Sinica , 2017;38(10):1317-1328.
14. A novel bibenzyl compound, 20C, protected mice from MPTP/p toxicity by regulating alpha-synuclein related inflammatory response. J Pharmacol Exp Ther . 2017;363(2):284-292.
15. Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome. Int Immunopharmacol . 2017 ;49:155-160.
16. Pathological α-Synuclein Exacerbates the Progression of Parkinson's Disease through Microglial Activation. Toxicol Lett. 2017; 265(4) :30-37.
